Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2014, Article ID 735751, 8 pages
http://dx.doi.org/10.1155/2014/735751
Research Article

Aromatic Amines Exert Contrasting Effects on the Anticoagulant Effect of Acetaldehyde upon APTT

Department of Chemistry, Bowling Green State University, Bowling Green, OH 43403, USA

Received 12 June 2014; Revised 29 September 2014; Accepted 30 September 2014; Published 8 December 2014

Academic Editor: Bashir A. Lwaleed

Copyright © 2014 La'Teese Hall et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. S. Brecher, “The effect of acetaldehyde on plasma,” in Comprehensive Handbook of Alcohol Related Pathology, V. R. Preedy and R. Watson, Eds., pp. 1223–1244, Academic Press, Elsevier Science, London, UK, 2005. View at Google Scholar
  2. H. Fraenkel-Conrat and H. S. Olcott, “Reaction of formaldehyde with proteins. VI. Crosslinking of amino groups with phenol, imidazole, or indole groups,” The Journal of Biological Chemistry, vol. 174, pp. 827–843, 1948. View at Google Scholar
  3. H. Fraenkel-Conrat and H. S. Olcott, “The reaction of formaldehyde with proteins. V. Cross-linking between amino and primary amide or guanidyl groups,” Journal of the American Chemical Society, vol. 70, no. 8, pp. 2673–2684, 1948. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Ratner and H. T. Clarke, “The action of formaldehyde upon cysteine,” Journal of the American Chemical Society, vol. 59, no. 1, pp. 200–206, 1937. View at Publisher · View at Google Scholar · View at Scopus
  5. S. J. Murrey and A. S. Brecher, “Interaction of biogenic amine hormones with acetaldehyde,” Digestive Diseases and Sciences, vol. 55, no. 1, pp. 21–27, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. A. S. Brecher and M. T. Adamu, “Short- and long-term effects of acetaldehyde on plasma,” Alcohol, vol. 26, no. 1, pp. 49–53, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. D. J. Tuma, T. Hoffman, and M. F. Sorrell, “The chemistry of acetaldehyde-protein adducts,” Alcohol and Alcoholism, vol. 1, pp. 271–276, 1991. View at Google Scholar · View at Scopus
  8. M. F. Sorrell, D. J. Tuma, and A. J. Barak, “Evidence that acetaldehyde irreversibly impairs glycoprotein metabolism in liver slices,” Gastroenterology, vol. 73, no. 5, pp. 1138–1141, 1977. View at Google Scholar · View at Scopus
  9. T. P. Enevoldson, “Recreational drugs and their neurological consequences,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 75, supplement 111, pp. iii9–iii15, 2004. View at Google Scholar
  10. K. Esse, M. Fossati-Bellani, A. Traylor, and S. Martin-Schild, “Epidemic of illicit drug use, mechanisms of action/addiction and stroke as a health hazard,” Brain and Behavior, vol. 1, no. 1, pp. 44–54, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. V. V. Upreti, N. D. Eddington, K.-H. Moon, B.-J. Song, and I. J. Lee, “Drug interaction between ethanol and 3,4-methylenedioxymethamphetamine (“ecstasy”),” Toxicology Letters, vol. 188, no. 2, pp. 167–172, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Izco, L. Orio, E. O'Shea, and M. I. Colado, “Binge ethanol administration enhances the MDMA-induced long-term 5-HT neurotoxicity in rat brain,” Psychopharmacology, vol. 189, no. 4, pp. 459–470, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. C. L. Galindo, M. A. Skinner, M. Errami et al., “Transcriptional profile of isoproterenol-induced cardiomyopathy and comparison to exercise-induced cardiac hypertrophy and human cardiac failure,” BMC Physiology, vol. 9, no. 1, article no. 23, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. L. C. Heather, A. F. Catchpole, D. J. Stuckey, M. A. Cole, C. A. Carr, and K. Clarke, “Isoproterenol induces in vivo functional and metabolic abnormalities; similar to those found in the infarcted rat heart,” Journal of Physiology and Pharmacology, vol. 60, no. 3, pp. 31–39, 2009. View at Google Scholar · View at Scopus
  15. X. Li, R. Zhou, P. Zheng et al., “Cardioprotective effect of matrine on isoproterenol-induced cardiotoxicity in rats,” Journal of Pharmacy and Pharmacology, vol. 62, no. 4, pp. 514–520, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. K. S. Kumaran and P. S. M. Prince, “Preventive effect of caffeic acid on lysosomal dysfunction in isoproterenol-induced myocardial infarcted rats,” Journal of Biochemical and Molecular Toxicology, vol. 24, no. 2, pp. 115–122, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Vennila and K. V. Pugalendi, “Efficacy of sesamol on plasma and tissue lipids in isoproterenol-induced cardiotoxicity in Wistar rats,” Archives of Pharmacal Research, vol. 35, no. 8, pp. 1465–1470, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Lalitha, P. Poornima, A. Archanah, and V. V. Padma, “Protective effect of neferine against isoproterenol-induced cardiac toxicity,” Cardiovascular Toxicology, vol. 13, no. 2, pp. 168–179, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Pipaliya and J. Vaghasiya, “Cardio protective effect of vitamin A against isoproterenol-induced myocardial infarction,” Journal of Nutritional Science and Vitaminology, vol. 58, no. 6, pp. 402–407, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Remla, P. V. G. Menon, P. A. Kurup, and S. Kumari, “Effect of ethanol administration on metabolism of lipids in heart and aorta in isoproterenol induced myocardial infarction in rats,” Indian Journal of Experimental Biology, vol. 29, no. 3, pp. 244–248, 1991. View at Google Scholar · View at Scopus
  21. L. D. Gottlieb, R. I. Horwitz, M. L. Kraus, S. R. Segal, and C. M. Viscoli, “Randomized controlled trial in alcohol relapse prevention: role of atenolol, alcohol craving, and treatment adherence,” Journal of Substance Abuse Treatment, vol. 11, no. 3, pp. 253–258, 1994. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Klapholz, “β-blocker use for the stages of heart failure,” Mayo Clinic Proceedings, vol. 84, no. 8, pp. 718–729, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. V. Hinstridge and T. M. Speight, “An overview of therapeutic interventions in myocardial infarction. Emphasis on secondary prevention,” Drugs, vol. 42, no. 2, pp. 8–20, 1991. View at Publisher · View at Google Scholar · View at Scopus
  24. M. E. Pedersen and J. R. Cockcroft, “The vasodilatory beta-blockers,” Current Hypertension Reports, vol. 9, no. 4, pp. 269–277, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. M. A. A. Saad, A. M. Abbas, V. Boshra, M. Elkhateeb, and I. A. El Aal, “Effect of Angiotensin II Type 1 receptor blocker, Candesartan, and β1 adrenoceptor blocker, Atenolol, on brain damage in ischemic stroke,” Acta Physiologica Hungarica, vol. 97, no. 2, pp. 159–171, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. B. Filipek, J. Krupinska, T. Librowski, K. Zebala, I. Piasecka, and W. Peikoszewski, “The effect of ethanol on the antiarrhythmic action of atenolol,” Polish Journal of Pharmacology and Pharmacy, vol. 41, no. 3, pp. 207–211, 1989. View at Google Scholar · View at Scopus
  27. H. Douard, B. Mora, and J.-P. Broustet, “Comparison of the anti-anginal efficacy of nicardipine and nifedipine in patients receiving atenolol: a randomized, double-blind, crossover study,” International Journal of Cardiology, vol. 22, no. 3, pp. 357–363, 1989. View at Publisher · View at Google Scholar · View at Scopus
  28. L. D. Gottlieb, “The role of beta blockers in alcohol withdrawal syndrome,” Postgraduate Medicine, no. 169–174, 1988. View at Google Scholar
  29. R. I. Horwitz, L. D. Gottlieb, and M. L. Kraus, “The efficacy of atenolol in the outpatient management of the alcohol withdrawal syndrome. Results of a randomized clinical trial,” Archives of Internal Medicine, vol. 149, no. 5, pp. 1089–1093, 1989. View at Publisher · View at Google Scholar · View at Scopus
  30. B. A. Johnson, “The role of serotonergic agents as treatments for alcoholism,” Drugs of Today, vol. 39, no. 9, pp. 665–672, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Sato, M. Kaji, N. Metoki, H. Yoshida, and K. Satoh, “Coagulation-fibrinolysis abnormalities in patients receiving antiparkinsonian agents,” Journal of the Neurological Sciences, vol. 212, no. 1-2, pp. 55–58, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Sandler, S. B. Carter, K. R. Hunter, and G. M. Stern, “Tetrahydroisoquinoline alkaloids: in vivo metabolites of L-dopa in man,” Nature, vol. 241, no. 5390, pp. 439–443, 1973. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Hirst, D. R. Evans, C. W. Gowdey, and M. A. Adams, “The influences of ethanol and other factors on the excretion of urinary salsolinol in social drinkers,” Pharmacology Biochemistry and Behavior, vol. 22, no. 6, pp. 993–1000, 1985. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Adachi, Y. Mizoi, T. Fukunaga, M. Kogame, I. Ninomiya, and T. Naito, “Effect of acetaldehyde on urinary salsolinol in healthy man after ethanol intake,” Alcohol, vol. 3, no. 3, pp. 215–220, 1986. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Naoi, W. Maruyama, and G. M. Nagy, “Dopamine-derived salsolinol derivatives as endogenous monoamine oxidase inhibitors: occurrence, metabolism, and function in human brains,” NeuroToxicology, vol. 25, no. 1-2, pp. 193–204, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. W. Maruyama, G. Sobue, K. Matsubara, Y. Hashizume, P. Dostert, and M. Naoi, “A dopaminergic neurotoxin, 1(R)2(N)-dimethyl-6,7-dihydroxy-1,2,34-tetrahydroisoquinoline, N-methyl (R) salsolinol and its oxidation product, 1,2(N)-dimethyl-6,7-dihydroxyisquinolinium ion, accumulate in the nigro-straiatal system of the human brain,” Neuroscience Letters, vol. 223, pp. 61–64, 1997. View at Google Scholar
  37. P. Batel, “The treatment of alcoholism in France,” Drug and Alcohol Dependence, vol. 39, supplement 1, pp. S15–S21, 1995. View at Publisher · View at Google Scholar · View at Scopus
  38. R. C. Elliott and J. P. Quilliam, “Some actions of centrally active and other drugs on the transmission of single nerve impulses through the isolated superior cervical ganglion preparation of the rabbit,” British Journal of Pharmacology and Chemotherapy, vol. 23, pp. 222–240, 1964. View at Google Scholar
  39. D. A. Brown and J. P. Quilliam, “The effects of some centrally acting drugs on ganglionic transmission in the cat,” The British Journal of Pharmacology and Chemotherapy, vol. 23, pp. 241–256, 1964. View at Google Scholar
  40. D. A. Brown and J. P. Quillian, “Observations on the mode of action of some central depressant drugs on transmission through the cat superior cervical ganglion,” British Journal of Pharmacology, vol. 23, pp. 257–272, 1964. View at Google Scholar